Immuron CEO Steven Lydeamore presented at AusBioInvest

MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer, Steven Lydeamore, presented at AusBioInvest 2023 on Monday, October 30th in the 9.40am – 10.35am session (AEST) at the Park Hyatt, Melbourne, Australia.

A copy of the presentation being made at AusBioInvest 2023 is available on the Company’s website.

This release has been authorised by the directors of Immuron Limited.


Steven Lydeamore
Chief Executive Officer
Ph: +61 (0)3 9824 5254

About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

For more information visit: